Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer

Immune checkpoint inhibitors are now a cornerstone of treatment for non-small cell lung cancer (NSCLC). Tissue-based assays, such as Programmed cell death protein 1 (PD-L1) expression or mismatch repair deficiency/microsatellite instability (MMRD/MSI) status, are approved as treatment drivers in var...

Full description

Bibliographic Details
Main Authors: Boris Duchemann, Jordi Remon, Marie Naigeon, Laura Mezquita, Roberto Ferrara, Lydie Cassard, Jean Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Edouard Auclin, Aude Desnoyer, Benjamin Besse, Nathalie Chaput
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
circulating biomarker
immune-checkpoint inhibitor
liquid biopsy
lung cancer
blood biomarker
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/12/12/3625

Internet

https://www.mdpi.com/2072-6694/12/12/3625

Similar Items